Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,173 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effects of canagliflozin on brain natriuretic peptide levels in patients with type 2 diabetes on peritoneal dialysis in Japan: protocol for a multicentre, prospective, randomised controlled trial (CARD-PD trial).
Matsuoka N, Nakazawa D, Nishio S, Cho KY, Maoka T, Kaneshima N, Yamamoto R, Yamamoto J, Shimamoto M, Makita M, Iriuda S, Igarashi K, Ito Y, Kato A, Yoshikawa J, Kudo T, Nagashima T, Ito YM, Atsumi T. Matsuoka N, et al. Among authors: nagashima t. BMJ Open. 2024 Nov 25;14(11):e084846. doi: 10.1136/bmjopen-2024-084846. BMJ Open. 2024. PMID: 39592158 Free PMC article.
Event-free survival at 36 months is a suitable endpoint for diffuse large B-cell lymphoma patients treated with immunochemotherapy: real-world evidence from the North Japan Hematology Study Group.
Izumiyama K, Inao T, Goto H, Harada S, Senjo H, Suto K, Hashiguchi J, Ogasawara R, Saga T, Igarashi T, Wakasa K, Kasahara I, Takeda Y, Yamaguchi K, Shigematsu A, Takahata M, Fujimoto K, Haseyama Y, Nagashima T, Sakai H, Kakinoki Y, Kurosawa M, Yokota I, Teshima T. Izumiyama K, et al. Among authors: nagashima t. Haematologica. 2024 Nov 1;109(11):3631-3640. doi: 10.3324/haematol.2023.284841. Haematologica. 2024. PMID: 38867578 Free PMC article.
Dominant-negative type of IKZF1 deletion showed a favorable prognosis in adult B-cell acute lymphoblastic leukemia.
Kimura H, Onozawa M, Yoshida S, Miyashita N, Yokoyama S, Matsukawa T, Hirabayashi S, Goto H, Endo T, Oguri S, Fujisawa S, Mori A, Kondo T, Hidaka D, Okada K, Ota S, Kakinoki Y, Tsutsumi Y, Yamamoto S, Miyagishima T, Hashiguchi J, Nagashima T, Ibata M, Wakasa K, Haseyama Y, Fujimoto K, Ishihara T, Sakai H, Teshima T. Kimura H, et al. Among authors: nagashima t. Ann Hematol. 2023 Nov;102(11):3103-3113. doi: 10.1007/s00277-023-05405-0. Epub 2023 Aug 19. Ann Hematol. 2023. PMID: 37597110
A novel nutritional index "simplified CONUT" and the disease risk index independently stratify prognosis of elderly patients with acute myeloid leukemia.
Senjo H, Onozawa M, Hidaka D, Yokoyama S, Yamamoto S, Tsutsumi Y, Haseyama Y, Nagashima T, Mori A, Ota S, Sakai H, Ishihara T, Miyagishima T, Kakinoki Y, Kurosawa M, Kobayashi H, Iwasaki H, Hashimoto D, Kondo T, Teshima T. Senjo H, et al. Among authors: nagashima t. Sci Rep. 2020 Nov 10;10(1):19400. doi: 10.1038/s41598-020-76250-8. Sci Rep. 2020. PMID: 33173122 Free PMC article.
Pretreatment evaluation of fluorescence resonance energy transfer-based drug sensitivity test for patients with chronic myelogenous leukemia treated with dasatinib.
Kondo T, Fujioka M, Tsuda M, Murai K, Yamaguchi K, Miyagishima T, Shindo M, Nagashima T, Wakasa K, Fujimoto N, Yamamoto S, Yonezumi M, Saito S, Sato S, Ogawa K, Chou T, Watanabe R, Kato Y, Takahashi S, Okano Y, Yamamoto J, Ohta M, Iijima H, Oba K, Kishino S, Sakamoto J, Ishida Y, Ohba Y, Teshima T; Inter-Michinoku Dasatinib Study Group (IMIDAS). Kondo T, et al. Among authors: nagashima t. Cancer Sci. 2018 Jul;109(7):2256-2265. doi: 10.1111/cas.13625. Epub 2018 May 29. Cancer Sci. 2018. PMID: 29719934 Free PMC article. Clinical Trial.
Rapid reduction in BCR-ABL1 transcript predicts deep molecular response in dasatinib-treated chronic-phase chronic myeloid leukaemia patients.
Murai K, Yamaguchi K, Ito S, Miyagishima T, Shindo M, Wakasa K, Inomata M, Nagashima T, Kondo T, Fujimoto N, Yamamoto S, Yonezumi M, Oyake T, Kowata S, Tsukushi Y, Mine T, Meguro K, Ikeda K, Watanabe R, Saito S, Sato S, Tajima K, Chou T, Kubo K, Oba K, Sakamoto J, Ishida Y; The Inter-Michinoku Dasatinib Study Group (IMIDAS). Murai K, et al. Among authors: nagashima t. Eur J Haematol. 2018 Jan;100(1):27-35. doi: 10.1111/ejh.12969. Epub 2017 Oct 16. Eur J Haematol. 2018. PMID: 28895203 Clinical Trial.
High CRP-albumin ratio predicts poor prognosis in transplant ineligible elderly patients with newly diagnosed acute myeloid leukemia.
Senjo H, Onozawa M, Hidaka D, Yokoyama S, Yamamoto S, Tsutsumi Y, Haseyama Y, Nagashima T, Mori A, Ota S, Sakai H, Ishihara T, Miyagishima T, Kakinoki Y, Kurosawa M, Kobayashi H, Iwasaki H, Hashimoto D, Kondo T, Teshima T. Senjo H, et al. Among authors: nagashima t. Sci Rep. 2022 May 25;12(1):8885. doi: 10.1038/s41598-022-12813-1. Sci Rep. 2022. PMID: 35614177 Free PMC article.
Prognostic impact of FLT3-ITD, NPM1 mutation and CEBPA bZIP domain mutation in cytogenetically normal acute myeloid leukemia: a Hokkaido Leukemia Net study.
Miyashita N, Onozawa M, Yoshida S, Kimura H, Takahashi S, Yokoyama S, Matsukawa T, Hirabayashi S, Fujisawa S, Mori A, Ota S, Kakinoki Y, Tsutsumi Y, Yamamoto S, Miyagishima T, Nagashima T, Ibata M, Wakasa K, Haseyama Y, Fujimoto K, Ishihara T, Sakai H, Kondo T, Teshima T. Miyashita N, et al. Among authors: nagashima t. Int J Hematol. 2023 Jul;118(1):36-46. doi: 10.1007/s12185-023-03567-1. Epub 2023 Feb 28. Int J Hematol. 2023. PMID: 36853451 Free article.
Non-age-related neoplastic loss of sex chromosome correlated with prolonged survival in real-world CBF-AML patients.
Mori A, Onozawa M, Hidaka D, Yokoyama S, Miyajima T, Yokoyama E, Ogasawara R, Izumiyama K, Saito M, Fujisawa S, Ota S, Kakinoki Y, Tsutsumi Y, Yamamoto S, Miyagishima T, Nagashima T, Iwasaki H, Kobayashi H, Haseyama Y, Kurosawa M, Morioka M, Teshima T, Kondo T. Mori A, et al. Among authors: nagashima t. Int J Hematol. 2022 Feb;115(2):188-197. doi: 10.1007/s12185-021-03238-z. Epub 2021 Nov 5. Int J Hematol. 2022. PMID: 34739701
Pharmacokinetics and pharmacodynamics of dasatinib in the chronic phase of newly diagnosed chronic myeloid leukemia.
Ishida Y, Murai K, Yamaguchi K, Miyagishima T, Shindo M, Ogawa K, Nagashima T, Sato S, Watanabe R, Yamamoto S, Hirose T, Saitou S, Yonezumi M, Kondo T, Kato Y, Mochizuki N, Ohno K, Kishino S, Kubo K, Oyake T, Ito S; Inter-Michinoku Dasatinib Study Group (IMIDAS). Ishida Y, et al. Among authors: nagashima t. Eur J Clin Pharmacol. 2016 Feb;72(2):185-93. doi: 10.1007/s00228-015-1968-y. Epub 2015 Oct 27. Eur J Clin Pharmacol. 2016. PMID: 26507546 Clinical Trial.
1,173 results